AIVEN
29.11.2022 09:02:41 CET | Business Wire | Press release
Aiven, the open source cloud data platform company, has announced several key senior leadership appointments who collectively are focused on helping deliver the company’s commitment to democratising access to the best open source technologies while reducing the environmental impact of cloud services.
These strategic new leadership roles span operations and strategy, product marketing, developer relations, and product management and include
- Katariina Korhonen, Vice President of Strategy and Operations
- Amy Krishnamohan, Vice President of Product Marketing
- Ian Massingham, Vice President of Developer Relations and Community
- Jonah Kowall, Vice President of Product Management
Oskari Saarenmaa, CEO and Co-founder at Aiven, comments on the appointments. “Aiven’s mission is to make developers’ lives better, by helping them build more sophisticated applications accessible to all. When starting Aiven, our goal was to build the company that we wanted to work for. Today we are delighted to be welcoming such a talented group to our leadership team and our wider Aiven community. Our ability to attract the best talent, while also supporting the career growth of our people continues to be instrumental in helping us develop new platform capabilities that bring us closer towards our goal of building more sustainable applications in the cloud.”
Katariina Korhonen has been appointed Vice President of Strategy and Operations to Aiven's Executive Leadership team. Katariina works closely with other senior executives and the board of directors and is focusing on building out Aiven’s corporate, operations, and sustainability strategy globally. Prior to her new role, Katariina spent the last six years in various executive roles at Smartly.
Amy Krishnamohan has also joined as Vice President of Product Marketing with the responsibility for Aiven’s product marketing direction and strategy, and nurturing and engaging with key stakeholders such as analysts, industry thought leaders, and strategic customers to increase the market awareness of Aiven. A Masters alumna of Carnegie Mellon University, Amy has gained diverse experience across product marketing and marketing strategy where she managed open-source database projects and other cloud-native databases. Prior to joining Aiven, she led product marketing strategies from major database companies such as MariaDB and Google Cloud.
Aiven also welcomes Ian Massingham as the company’s Vice President of Developer Relations and Community focusing on further building Aiven’s relationship with the developer community and ensuring that our programs align with our mission of making developers’ lives better. Prior to joining Aiven, Ian led the Developer Relations & Community team at MongoDB. Before that, he played an integral role in establishing and scaling the evangelism and developer relations function at AWS and led Worldwide Solutions Architecture for Startup customers for the final 18 months of his tenure at AWS.
Jonah Kowall has also joined as Aiven’s new Vice President of Product Management. In his role, Jonah will lead and execute the product strategy and head the product team responsible for platform enhancements to support ongoing growth in Aiven’s customer base. Previously a Chief Technology Officer at Logz.io and several other startups, Jonah’s background includes being a Research VP at Gartner and a regular contributor and maintainer of the Open Source Jaeger and OpenTelemetry projects. Jonah joins Aiven and brings with him a wealth of knowledge on all things “observability”.
This latest announcement of senior leadership expansion closely follows the appointment of Olivier van Grembergen as Regional Vice President (RVP) of Aiven Asia Pacific (APAC), announced earlier in October to drive continued growth in the region.
To learn more about Aiven, please visit https://aiven.io/
Free Trial https://console.aiven.io/signup
About Aiven
Headquartered in Helsinki and with hubs in Berlin, Boston, Paris, Singapore, Sydney, Tokyo, and Toronto, Aiven provides managed open source data technologies, like PostgreSQL, Apache Kafka and OpenSearch, on all major clouds. Through Aiven, developers can do what they do best: create applications. Meanwhile, Aiven does what they do best: manage cloud data infrastructure. Aiven enables customers to drive business results from open source that trigger true transformations far beyond their own backyard. Most recently, Aiven achieved a $3B valuation and has now raised $420M total funding backed by its investors Atomico, Earlybird, Eurazeo, IVP, Lifeline, Salesforce Ventures, and World Innovation Lab.
To learn more about Aiven, visit aiven.io and follow @aiven_io on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005090/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom